

Prof. HAKAN HARPUTLUOĞLU

Personal Information

Email: hakan.harputlu@inonu.edu.tr

Web: <https://avesis.inonu.edu.tr/hakan.harputlu>

International Researcher IDs

ORCID: 0000-0001-8537-5941

Yoksis Researcher ID: 117830

Education Information

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2004 - 2007

Expertise In Medicine, Inonu University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1999 - 2004

Undergraduate, Hacettepe University, Tıp Fakültesi, Turkey 1991 - 1998

Academic Titles / Tasks

Professor, Inonu University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2017 - Continues

Associate Professor, Inonu University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2012 - 2017

Assistant Professor, Inonu University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2010 - 2012

Assistant Professor, Inonu University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2007 - 2008

Courses

ONKOLOJİK HASTAYA YAKLAŞIM, Undergraduate, 2020-2021

KANSER TARAMA YÖNTEMLERİ VE TÜMÖR BELİRLEYİCİLER, Undergraduate, 2020-2021

KEMOTERAPİK İLAÇLAR, Undergraduate, 2020-2021

TÜMÖR MARKERLERİ, Undergraduate, 2020-2021

AKCİĞER KANSERİ, Undergraduate, 2020-2021

KEMOTERAPİ PRENSİPLERİ, Undergraduate, 2020-2021

TÜMÖR MARKERLERİ, Undergraduate, 2019-2020

KEMOTERAPİ PRENSİPLERİ, Undergraduate, 2019-2020

KANSER TARAMA YÖNTEMLERİ VE TÜMÖR BELİRLEYİCİLER, Undergraduate, 2019-2020

KEMOTERAPİK İLAÇLAR, Undergraduate, 2019-2020

AKCİĞER KANSERİ, Undergraduate, 2019-2020

ONKOLOJİK HASTAYA YAKLAŞIM, Undergraduate, 2019-2020

AKCİĞER KANSERİ, Undergraduate, 2017 - 2018

kanser tarama yöntemleri ve tümör belirleyiciler, Undergraduate, 2017 - 2018

onkolojik hastaya yaklaşım, Undergraduate, 2017 - 2018

KEMOTERAPOTİK İLAÇLAR, Undergraduate, 2017 - 2018

kemoterapi prensipleri, Undergraduate, 2017 - 2018

TÜMÖR MARKERLERİ, Undergraduate, 2017 - 2018

onkolojik hastaya yaklaşım, Undergraduate, 2017-2018

kemoterapi prensipleri, Undergraduate, 2017-2018

KEMOTERAPOTİK İLAÇLAR, Undergraduate, 2017-2018

TÜMÖR MARKERLARI, Undergraduate, 2017-2018

kanser tarama yöntemleri ve tümör belirleyiciler, Undergraduate, 2017-2018

AKCİĞER KANSERİ, Undergraduate, 2017-2018

onkolojik aciller, Undergraduate, 2013-2014

gastrointestinal kanserler, Undergraduate, 2012-2013

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).**
Bilici A., Olmez O. F., Sezer A., Oksuzoglu B., Kaplan M. A., Karadurmus N., Cubukcu E., Sendur M. A. N., Aksoy S., Erdem D., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- II. **Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.**
Yildirim M. E., Karaca M., Artac M., Cicin I., Geredeli C., Alacacioglu A., Simsek E. T., Bilici A., Harputluoglu H., Ozcelik M., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- III. **Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial**
Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., Castellano D., Hussain S. A., Flechon A., Bamias A., et al.
LANCET ONCOLOGY, vol.21, no.1, pp.105-120, 2020 (SCI-Expanded)
- IV. **Is excision repair cross-complementation Group1 expression a biological marker in nasopharynx carcinoma**
AKSOY A., Elkiran E. T., Harputluoglu H., Dagli A. F., Isikdogan A., Urakci Z.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.15, no.3, pp.550-555, 2019 (SCI-Expanded)
- V. **POSTERIOR REVERSIBLE LEUKOENCEPHALOPATHY SYNDROME DEVELOPING SECONDARY TO SUNITINIB THERAPY IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA**
Kaplan N. B., HARPUTLUOĞLU H., Dikilitas M., ELKIRAN E. T., TEMELLİ Ö.
ACTA MEDICA MEDITERRANEA, vol.34, no.1, pp.39-42, 2018 (SCI-Expanded)
- VI. **Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial**
Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., Castellano D., Hussain S., Flechon A., Bamias A., et al.
LANCET, vol.390, no.10109, pp.2266-2277, 2017 (SCI-Expanded)
- VII. **Drug induced autoimmune hepatitis: A Single Center Experience**
BİLGİÇ Y., HARPUTLUOĞLU H., YILMAZ C., KARADAĞ N., ÇAĞIN Y. F., AKBULUT A. S., SEÇKİN Y., KUTLU O., YILDIRIM O., HARPUTLUOĞLU M. M. M.
BIOMEDICAL RESEARCH-INDIA, vol.28, no.15, pp.6528-6532, 2017 (SCI-Expanded)
- VIII. **Drug induced autoimmune hepatitis: a single center experience.**
Bilgic Y., Harputluoglu H., Yilmaz C., Karadag Soylu N., Cagin Y. F., Akbulut S., Seckin Y., Kutlu O., Yildirim O., Harputluoglu M.
BIOMEDICAL RESEARCH-INDIA, vol.28, no.15, pp.6528-6532, 2017 (SCI-Expanded)
- IX. **Does the tumor necrosis factor a predictor factor in patients with chronic hepatitis B and C**
Bilgic Y., Seckin Y., Cagin Y. F., Yildirim O., Yilmaz C., Harputluoglu M., Harputluoglu H., Akbulut S., Sahin A.
BIOMEDICAL RESEARCH-INDIA, vol.28, no.4, pp.1683-1688, 2017 (SCI-Expanded)

- X. **Estimation of risk factors associated with colorectal cancer: an application of knowledge discovery in databases**
Firat F., ARSLAN A. K., ÇOLAK C., HARPUTLUOĞLU H.
KUWAIT JOURNAL OF SCIENCE, vol.43, no.2, pp.151-161, 2016 (SCI-Expanded)
- XI. **Factors Affecting Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis**
HARPUTLUOĞLU H., Kaplan N., Dikilitas M., Yagar Y.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.4, pp.199-205, 2016 (SCI-Expanded)
- XII. **Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology**
Bilici A., Ozturk T., Turkmen E., Odabas H., Cihan S., Selcukbiricik F., ERDOĞAN B., Urakci Z., Kandemir N., Bayoglu I. V., et al.
WORLD JOURNAL OF UROLOGY, vol.33, no.10, pp.1613-1622, 2015 (SCI-Expanded)
- XIII. **Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers**
Baykara M., BENEKLİ M., Ekinci O., Irkkan S. C., Karaca H., Demirci U., AKINCI M. B., Unal O. U., DANE F., Turkoz F. P., et al.
JOURNAL OF GASTROINTESTINAL SURGERY, vol.19, no.9, pp.1565-1571, 2015 (SCI-Expanded)
- XIV. **Cutaneous melanoma in Turkey: analysis of 1157 patients in the Melanoma Turkish Study**
Abali H., ÇELİK İ., Karaca B., TURNA Z. H., Saglam E. K., Akman T., Oztop I., COŞKUN H. Ş., Turhal N. S., Sezer A., et al.
JOURNAL OF BUON, vol.20, no.4, pp.1137-1141, 2015 (SCI-Expanded)
- XV. **Outcome of 561 non-metastatic triple negative breast cancer patients: Multi-center experience from Turkey**
Budakoglu B., Altundag K., Aksoy S., Kaplan M. A., Ozdemir N. Y., Berk V., ÖZKAN M., Algin E., Kandemir N., DOĞU G. G., et al.
JOURNAL OF BUON, vol.19, no.4, pp.872-878, 2014 (SCI-Expanded)
- XVI. **Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO)**
Cetin B., BENEKLİ M., Turker I., Koral L., Ulas A., DANE F., Oksuzoglu B., Kaplan M. A., Koca D., Boruban C., et al.
JOURNAL OF CHEMOTHERAPY, vol.26, no.5, pp.300-305, 2014 (SCI-Expanded)
- XVII. **Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience**
KEFELİ U., BENEKLİ M., Sevinc A., Yildiz R., Kaplan M. A., Ciltas A., Balakan O., Isikdogan A., Coskun U., DANE F., et al.
ONCOLOGY LETTERS, vol.6, no.2, pp.605-611, 2013 (SCI-Expanded)
- XVIII. **Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO)**
Demirci U., Tufan G., Aktas B., Balakan O., ALACACIOĞLU A., DANE F., ENGİN H., Kaplan M. A., Gunaydin Y., Ozdemir N. Y., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.139, no.5, pp.829-835, 2013 (SCI-Expanded)
- XIX. **Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients**
Uncu D., Aksoy S., Cetin B., Yetisyigit T., Ozdemir N., Berk V., DANE F., Inal A., HARPUTLUOĞLU H., Budakoglu B., et al.
ONCOLOGY, vol.84, no.4, pp.240-245, 2013 (SCI-Expanded)
- XX. **Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience**
Cetin B., BENEKLİ M., Oksuzoglu B., Koral L., Ulas A., DANE F., Turker I., Kaplan M. A., Koca D., Boruban C., et al.
ONKOLOGIE, vol.35, no.12, pp.740-745, 2012 (SCI-Expanded)
- XXI. **Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients**
ELKIRAN E. T., Kaplan M. A., Sevinc A., Aksoy S., Demirci U., Seker M., HARPUTLUOĞLU H., Ozdemir N. Y., Isik F., Ulas A., et al.
MEDICAL ONCOLOGY, vol.29, no.5, pp.3147-3154, 2012 (SCI-Expanded)

Articles Published in Other Journals

- I. **Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers**
Gulmez A., HARPUTLUOĞLU H.
JOURNAL OF GASTROINTESTINAL CANCER, vol.54, no.1, pp.11-19, 2023 (ESCI)
- II. **A rare granular cell tumor of the vulva: a case report**
Bozdogan Kaplan N., Dursun I. H., Dikilitas M., HARPUTLUOĞLU H., YILMAZ E., Sahin N.
TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY, vol.30, no.2, pp.78-81, 2015 (ESCI)

Refereed Congress / Symposium Publications in Proceedings

- I. **EGFR-targeted treatments in patients with metastatic colorectal cancer: Experience of panitumumab.**
Gumus M., Geredeli C., Ucar M., Kaya S., Demir H., Unal O. U., Degirmenci M., Dogu G. G., Turan N., Yildirim N., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35
- II. **ESTIMATION OF RISK FACTORS ASSOCIATED WITH COLORECTAL CANCER AN APPLICATION OF KNOWLEDGE DISCOVERY IN DATABASES**
FIRAT F., ARSLAN A. K., ÇOLAK C., HARPUTLUOĞLU H.
International Symposium on Econometrics, Operations Research and Statistics, 2 - 04 June 2016
- III. **Breast cancer subtypes and the risk of distant relapse after breast conserving surgery or mastectomy: An Anatolian Society of Medical Oncology study.**
Kaplan M. A., Urakci Z., Uncu D., Dane F., Ozkan M., Akman T., Harputluoglu H., Oksuzoglu B., Kucukoner M., Ozdemir N., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- IV. **Results of observational study to determine K-ras mutation rates in 2458 patients with metastatic colorectal cancer in Turkey (TURKRAS Study).**
Gumus M., Dane F., Karabulut B., Uygun K., Aydin K., Orhan B., Oksuzoglu B., Tarhan O., Buyukberber S., Okutur K., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- V. **Frequency and risk factors of potential drug interactions in breast cancer patients.**
Acar F., Dursun B. H., Harputluoglu H., Yigit A., Kilic M. S., Elkiran E. T.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- VI. **The effect of front-line chemotherapy on overall survival in patients with malignant pleural mesothelioma.**
Elkiran E. T., Sevinc A., Harputluoglu H.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31

Supported Projects

HARPUTLUOĞLU H., Other International Funding Programs, TEKRARLAYAN METASTATİK HNSCC GÖNÜLLÜLERİNDE BİRİNCİ BASAMAK TEDAVİ OLARAK PEMBROLİZUMAB, 2015 - Continues
HARPUTLUOĞLU H., Other International Funding Programs, lokal ileri veya metastatik mesane kanserinde atelozumab tedavisinin etkinliği, 2015 - Continues

HARPUTLUOĞLU H., Other International Funding Programs, HER2 POZİTİF METASTAİK GASTROÖZOFAGEAL BİLEŞKE VE GASTRİK KANSER HASTALARINDA KEMOTERAPİ İLE KOMBİNASYON HALİNDE VERİLEN PERTUZUMAB IN ETKİNLİĞİNİN VE GÜVENLİLİĞİNİN DEĞERLENDİRİLDİĞİ ÇİFT KÖR PLASEBO KONTROLLÜ RANDOMİZE ÇOK MERKEZLİ FAZ III ÇALIŞMASI, 2015 - Continues

HARPUTLUOĞLU H., Project Supported by Higher Education Institutions, METASTATİK KOLAN KOLAREKTAL KORSİNOMLU HASTALARIN İNCELENMESİ, CERBB-2 POZİTİFLİĞİNİN PROGNOZ ETKİSİNİN ARAŞTIRILMASI, 2016 - 2019

ELKIRAN E. T., HARPUTLUOĞLU H., KAHRAMAN A., Other International Funding Programs, Platin Bazlı Tedavi Sırasında Ya da Sonrasında Progresyon Gözlenen, Lokal İleri Ya da Cerrahi Rezeke Edilemeyen Ya da Metastatik Ürotelyal Hücreli Karsinom Hastalarında, Ramusirumab ile Dosetaksel ve Plasebo ile Dosetaksel'in Karşılaştırıldığı Plasebo-Kontrollü, Randomize, Çift-Kör, Faz 3 Çalışma, 2015 - 2017

Metrics

Publication: 30

Citation (WoS): 145

Citation (Scopus): 162

H-Index (WoS): 7

H-Index (Scopus): 7